PTC Therapeutics Target Price

Where could PTCT trade next? Consensus target price: $100.

Get informed when a big investor buys or sells

+ Follow

Share Price

$71.97

Average Target Price

$100.67

39.9% upside

6 analysts in the last 4 months

High: $130 | Low: $85

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-31	Morgan Stanley	$104	44.5% upside
2026-07-31	Wells Fargo	$106	47.3% upside
2026-07-16	Cantor Fitzgerald	$130	80.6% upside
2026-07-07	RBC Capital	$85	18.1% upside
2026-05-27	Jefferies	$85	18.1% upside
2026-05-08	Morgan StanleyJudah Frommer	$94	30.6% upside
2026-04-10	Raymond JamesTiago Fauth	$108	50.1% upside
2026-02-23	Morgan Stanley	$92	27.8% upside
2026-02-23	BarclaysEliana Merle	$120	66.7% upside
2026-02-20	RBC CapitalBrian Abrahams	$82	13.9% upside
2026-02-20	Wells Fargo	$86	19.5% upside
2026-01-27	Barclays	$119	65.3% upside
2026-01-08	Morgan Stanley	$90	25.1% upside
2025-12-01	RBC Capital	$91	26.4% upside
2025-11-05	Goldman Sachs	$50	30.5% downside
2025-11-05	Wells FargoTiago Fauth	$93	29.2% upside
2025-11-05	BarclaysGena Wang	$68	5.5% downside
2025-10-28	JefferiesKelly Shi	$77	7% upside
2025-08-08	Robert W. BairdJoel Beatty	$70	2.7% downside
2025-05-07	Robert W. BairdJoel Beatty	$66	8.3% downside
2025-01-07	RBC CapitalBrian Abrahams	$58	19.4% downside
2024-11-27	Robert W. BairdJoel Beatty	$52	27.7% downside
2024-10-11	Morgan StanleyJeffrey Hung	$45	37.5% downside
2024-08-26	UBSColin Bristow	$47	34.7% downside
2024-07-12	Morgan StanleyJeffrey Hung	$32	55.5% downside
2024-05-20	Goldman SachsPaul Choi	$32	55.5% downside
2024-05-20	JefferiesKelly Shi	$46	36.1% downside
2024-04-26	Morgan StanleyJeffrey Hung	$30	58.3% downside
2022-12-14	Goldman Sachs	$35	51.4% downside
2022-06-23	RBC CapitalBrian Abrahams	$46	36.1% downside
2022-04-05	Cantor FitzgeraldKristen Kluska	$63	12.5% downside
2021-08-31	UBSColin Bristow	$45	37.5% downside

PTC Therapeutics (PTCT) FAQ

PTC Therapeutics (PTCT) currently reports a target price of $100. Use the charts on this page to explore PTC Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for PTC Therapeutics is $100, about 39.9% upside from the current share price of $71.97. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $100, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for PTC Therapeutics, and consider following PTCT for alerts when major investors trade the stock.

PTC Therapeutics is classified in the Healthcare sector. On target price, it currently shows $100. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PTCT with unrelated industries.